Semaglutide vs HGH 191AA

Semaglutide and HGH 191AA are both well-characterized peptides with distinct research applications. Semaglutide, a synthetic GLP-1 analog, is backed by large-scale clinical programs (STEP, SUSTAIN) demonstrating efficacy in weight management and glycemic control. HGH 191AA, identical to endogenous growth hormone, is FDA-approved for deficiency states but lacks robust evidence for anti-aging or body composition enhancement in healthy individuals. Researchers must weigh their differing mechanisms, evidence levels, and safety profiles when designing studies.

Semaglutide acts as a GLP-1 receptor agonist with 94% sequence homology to human GLP-1, enhancing insulin secretion and delaying gastric emptying. Its molecular weight is ~4113.6 g/mol (C187H291N45O59). FDA-approved for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), and non-cirrhotic MASH (Wegovy), it is supported by the STEP and SUSTAIN trials involving thousands of patients. Key claims include significant weight loss, improved blood sugar control, and reduced cardiovascular risk. No generic is available, and the FDA has warned about counterfeit products.

HGH 191AA (somatropin) is a 191-amino acid recombinant polypeptide (MW ~22,124 g/mol) identical to endogenous growth hormone. FDA-approved for growth hormone deficiency in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and HIV-associated wasting, it is distinguished from the older 192-amino acid variant (somatrem) by lower immunogenicity. In the peptide community, it is often studied for anti-aging and body composition, though evidence for these uses in healthy individuals remains limited and controversial.

Semaglutide and HGH 191AA target distinct research domains with minimal overlap. Semaglutide is primarily investigated in metabolic health, weight management, and cardiovascular outcomes, leveraging its GLP-1 agonism. HGH 191AA is studied in anti-aging, longevity, and body composition, focusing on growth hormone pathways. While both may influence body composition, their mechanisms and evidence bases differ fundamentally, making direct comparison challenging.

Semaglutide: Common (5%+ in trials) adverse effects include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are dose-dependent and transient. Additional effects include upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, and tiredness. Serious but rare risks include pancreatitis, gallbladder disease, and severe allergic reactions. HGH 191AA: Common effects include injection site reactions, fluid retention, joint pain/stiffness, and carpal tunnel syndrome. Metabolic concerns include insulin resistance and hyperglycemia, which may precipitate diabetes. Endocrine effects include gynecomastia and unmasking of central hypothyroidism. Both peptides require careful monitoring in research settings.